Benzinga | May 6, 2021 08:43AM EDT

Adaptimmune Therapeutics Q1 EPS $(0.04) Beats $(0.25) Estimate, Sales $434.00K Miss $1.83M Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. This is unchanged from the same period last year. The company reported quarterly sales of $434.00 thousand which missed the analyst consensus estimate of $1.83 million by 76.28 percent. This is a 42.97 percent decrease over sales of $761.00 thousand the same period last year.